Pluri Inc. (PLUR): Cash & Equivalents
$3.53M
As of 2026-06-30
-13.0%
3-year compound annual growth
-35.3%
5-year compound annual growth
-5.5%
10-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2026-06-30 | $3.53M | -40.1% | 2026-09-10, Balance as of period end |
| 2025-06-30 | $5.89M | -13.1% | 2026-09-10, Balance as of period end |
| 2024-06-30 | $6.78M | +26.5% | 2025-09-17, Balance as of period end |
| 2023-06-30 | $5.36M | -45.1% | 2024-09-18, Balance as of period end |
| 2022-06-30 | $9.77M | -68.7% | 2023-09-12, Balance as of period end |
| 2021-06-30 | $31.24M | +277.8% | 2022-09-21, Balance as of period end |
| 2020-06-30 | $8.27M | +101.4% | 2021-09-13, Balance as of period end |
| 2019-06-30 | $4.11M | -53.5% | 2020-09-10, Balance as of period end |
| 2018-06-30 | $8.82M | +87.4% | 2019-09-12, Balance as of period end |
| 2017-06-30 | $4.71M | -24.4% | 2019-09-12, Balance as of period end |
| 2016-06-30 | $6.22M | -72.5% | 2018-09-12, Balance as of period end |
| 2015-06-30 | $22.63M | +403.6% | 2017-09-07, Balance as of period end |
| 2014-06-30 | $4.49M | -50.1% | 2016-09-07, Balance as of period end |
| 2013-06-30 | $9.01M | -4.1% | 2015-09-09, Balance as of period end |
| 2012-06-30 | $9.39M | -78.1% | 2014-09-11, Balance as of period end |
| 2011-06-30 | $42.83M | n/m | 2013-09-11, Balance as of period end |
| 2010-06-30 | $1.58M | n/a | 2012-09-10, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Pluri Inc. (PLUR) | 2026-06-30 | $3.53M | -40.1% |
| Prokidney Corp. (PROK) | 2025-12-31 | $108.54M | +9.5% |
| ImageneBio, Inc. (IMA) | 2025-12-31 | $94.53M | +680.1% |
| Inhibrx Biosciences, Inc. (INBX) | 2025-12-31 | $124.22M | -18.6% |
| Scinai Immunotherapeutics Ltd. (SCNI) | 2025-12-31 | $1.66M | -15.4% |
| Outlook Therapeutics, Inc. (OTLK) | 2025-09-30 | $8.08M | -45.9% |
| Cardiff Oncology, Inc. (CRDF) | 2025-12-31 | $17.47M | -66.1% |
| Humacyte, Inc. (HUMA) | 2025-12-31 | $50.50M | +12.4% |
| Aligos Therapeutics, Inc. (ALGS) | 2025-12-31 | $18.30M | -50.5% |
Compare PLUR, PROK, IMA, INBX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗